Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shannon Egan

Physician Assistant Rock Hill, SC Physician Assistant

NPI 1093234791 CMS profile 10861184

1656 Riverchase Blvd, Ste 1400, Rock Hill, SC 29732

Open in the dashboard

General payments

$6,958

273 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shannon Egan of Rock Hill, SC is reported in the CMS Open Payments database as having received $6,958 across 273 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19 1
2024 General $417 7
2023 General $2,388 105
2022 General $1,814 87
2021 General $2,319 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shannon Egan
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Shannon Egan were reported at $19. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Shannon Egan Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,319 $132 $37–$438 $132
2022 $1,814 $155 $48–$522 $149
2023 $2,388 $167 $52–$557 $160
2024 $417 $178 $55–$600 $164
2025 $19 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $2,349 54 payments
  2. Genzyme Corporation $361 15 payments
  3. Janssen Biotech, Inc. $347 18 payments
  4. Genentech USA, Inc. $272 16 payments
  5. Astellas Pharma US Inc $270 6 payments
  6. GlaxoSmithKline, LLC. $189 6 payments
  7. AstraZeneca Pharmaceuticals LP $178 11 payments
  8. Celgene Corporation $171 10 payments
  9. Lilly USA, LLC $158 8 payments
  10. Merck Sharp & Dohme Corporation $157 9 payments
  11. Other $2,508 120 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,789 249 payments
  2. Long term medical supply or device loan $1,781 20 payments
  3. Education $388 4 payments
Products named General payments · program years 2021–2025
  1. KISQALI $1,761 30 payments
  2. JEVTANA $259 7 payments
  3. LIBTAYO $237 12 payments
  4. DARZALEX $199 11 payments
  5. KEYTRUDA $157 9 payments
  6. BLENREP $151 4 payments
  7. IMBRUVICA Oncology $150 7 payments
  8. FEMARA $148 10 payments
  9. IMBRUVICA Oncology $147 8 payments
  10. PROMACTA $141 9 payments
  11. Other $4,700 256 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

206

Median for Physician Assistant: 241

Drug cost

$21,001

Median for Physician Assistant: $4,110

Branded share of claims

16%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 22 $18,702
Ondansetron Hcl Generic 25 $620
Hydroxyurea Generic 32 $403
Letrozole Generic 13 $244
Potassium Chloride Generic 17 $187
Gabapentin Generic 16 $179
Anastrozole Generic 17 $176
Ondansetron Odt Ondansetron Brand 11 $159
Olanzapine Generic 11 $120
Prochlorperazine Maleate Generic 17 $114

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$666,403

Of which drugs: $628,987

Medicare patients

268

Average age 74

Services billed

28,818

140 women, 128 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Cancer 47%
Ischemic heart disease 40%
Diabetes 35%
Depression 26%
Chronic kidney disease 24%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 Office 13 10,710 $3,027
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 19 258 $23
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 18 296 $21

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $333
$333 — —
Orserdu
  • Stemline Therapeutics Inc. $84
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

273 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record